RxDoctor Payments Data

John Golding, MD

Family Medicine · Reidsville, NCNPI 1063494151

Payments from drug & device makers

$6,295in general payments, 2019–2025

Across 276 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$882
  • Boehringer Ingelheim$447
  • Esperion Therapeutics, Inc.$328
  • Bayer$313
  • GSK$251
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$6,22999%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,295 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$72,331
Medicare patients
209
Services billed
5,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban223$186,975
JanuviaSitagliptin Phosphate104$102,875
MounjaroTirzepatide77$82,967
XareltoRivaroxaban84$82,960
JanumetSitagliptin Phos/Metformin Hcl36$42,813
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$35,139
FarxigaDapagliflozin Propanediol34$26,091
JardianceEmpagliflozin19$23,513
OzempicSemaglutide18$20,322
TradjentaLinagliptin14$16,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,444
LinzessLinaclotide17$12,238
Levothyroxine Sodium1,024$9,575
Rosuvastatin Calcium647$8,614
Repatha SureclickEvolocumab15$8,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Abrysvo$206$196,873263 claims
MerckJanuvia, Janumet$136$145,688140 claims
Lilly USA, LLCMounjaro$882$82,96777 claims
Johnson & JohnsonXarelto$48$82,96084 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$1,588$68,949100 claims
Boehringer IngelheimJardiance, Tradjenta$447$39,52333 claims
GSKTrelegy Ellipta, Shingrix$251$22,77155 claims
Novo NordiskOzempic$203$20,32218 claims
AbbVieLinzess, Synthroid$247$16,04060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Reidsville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →